Diagnosis of Multiple Myeloma
Robert A. Kyle and Daniel E. Bergsagel

Epidemiology of Multiple Myeloma and Related Disease
Brian G. M. Durie

Characterization of the Myeloma Clone
Robert A. Vescio and James R. Berenson

Oncogenesis of Multiple Myeloma
Johannes Drach, Sonja Seidl, Jutta Ackermann, and Hannes Kaufmann

Cytokines in Multiple Myeloma
John De Vos and Bernard Klein

Monoclonal Gammopathy of Undetermined Significance
Robert A. Kyle

Tumor Burden: Staging and Prognostic Factors
Douglas E. Joshua

Treatment of Multiple Myeloma
Meletios A. Dimopoulos and Robert A. Kyle

Dose-Intensive Therapy With Autologous Stem Cell Transplantation for Patients With Multiple Myeloma
Jean-Luc Harousseau, Michel Attal, and Gary J. Schiller

Allogeneic Transplantation in Multiple Myeloma
Gösta Gahrton, Kenneth C. Anderson, and William Bensinger

Immunological Approaches to Multiple Myeloma
Hakan Mellstedt, Maurizio Bendandi, Anders Österborg, and Larry W. Kwak

Remission Maintenance in Multiple Myeloma
Heinz Ludwig and Niklas Zojer

Myeloma Bone Disease
James R. Berenson

Renal Diseases Associated With Multiple Myeloma and Related Plasma Cell Dyscrasias
Alan Solomon, Deborah T. Weiss, and Guillermo A. Herrera

Pathogenesis and Treatment of Anemia
Heinz Ludwig and Anders Österborg

New Therapeutic Approaches to Myeloma
Terry H. Landowski, William S. Dalton, and Sydney E. Salmon

Index

Expert physicians and clinical researchers summarize and explain all the recent advances in the biology and treatment of bone marrow-based malignancy. On the biological side, the authors show the characteristics of the malignant cell and describe the significant roles played by oncogenic changes, chromosomal anomalies, Kaposi's sarcoma herpes virus, and cytokines. New epidemiological findings and prognostic factors are also analyzed. On the clinical side, the authors provide a comprehensive review of conventional treatment regimens, as well as a discussion of newer experimental approaches involving immunologic targeting, inhibitors of drug resistance, and antitumor agents.